Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
AG 1879 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of AKT1 protein]; cyanidin-3-O-beta-glucopyranoside inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of AKT1 protein]
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of AKT1 mRNA; 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of AKT1 protein
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of and results in decreased phosphorylation of AKT1 protein; 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased activity of and results in increased phosphorylation of AKT1 protein; 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of AKT1 protein; EGFR mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of AKT1 protein]; MUC1 mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of AKT1 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased activity of and results in increased phosphorylation of AKT1 protein]
